10-K: PMI Reports Strong 2025 Growth Driven by Smoke-Free Products

Philip Morris International reports a significant increase in net revenues and diluted EPS for 2025, fueled by robust growth in its smoke-free product portfolio and strategic market expansions.

Summary

• Net revenues for the year ended December 31, 2025, reached $40.6 billion, an increase of 7.3% from 2024, or 6.5% excluding currency and acquisitions/divestitures.
• Diluted earnings per share (EPS) for 2025 was $7.26, a substantial 60.6% increase compared to $4.52 in 2024.
• Operating income grew by 11.1% to $14.892 billion in 2025, or 9.3% excluding currency and acquisitions/divestitures.
• Total shipment volume, including cigarettes and smoke-free products, increased by 1.4% to 786.5 billion equivalent units in 2025.
• Smoke-free product (SFP) shipment volume surged by 12.8% to 179.1 billion equivalent units, while cigarette shipment volume declined by 1.5% to 607.4 billion units.
• Oral smoke-free product shipments increased by 21.4% to 1,240.0 million cans in 2025, predominantly driven by ZYN nicotine pouches in the U.S.
• The company reacquired full commercialization rights for IQOS in the U.S. as of April 30, 2024, and began selling IQOS 3.0 in Austin, Texas, on March 27, 2025.
• The U.S. Food and Drug Administration (FDA) authorized the marketing of Swedish Match's General snus and ZYN nicotine pouches, and versions of PMI's IQOS devices and consumables, with some also receiving Modified Risk Tobacco Product (MRTP) authorizations.
• Restructuring charges totaled $241 million in 2025, primarily due to the cessation of combustible tobacco production in two German factories.
• A goodwill impairment charge of $41 million was recorded in the Europe segment in 2025.
• A pre-tax charge of $176 million was recorded in 2025 related to the Germany excise tax classification litigation for TEREA consumables.
• The effective tax rate decreased to 19.7% in 2025 from 24.7% in 2024.
• Net cash provided by operating activities was $12.2 billion in 2025, essentially flat compared to 2024, with higher working capital requirements partly offset by higher currency-neutral net earnings.
• Total debt stood at $48.8 billion at December 31, 2025, up from $45.7 billion at December 31, 2024.
• The company implemented an evolved organizational model with two primary business units, International and U.S., effective January 1, 2026, realigning reportable segments accordingly.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong performance, driven by significant growth in smoke-free products and effective management of a complex regulatory and geopolitical landscape, despite ongoing challenges in combustible tobacco.

Positives

• Net revenues increased by 7.3% to $40.6 billion in 2025, demonstrating strong top-line growth.
• Diluted EPS saw a significant increase of 60.6% to $7.26 in 2025, reflecting improved profitability.
• Smoke-free product (SFP) shipment volume grew robustly by 12.8%, indicating successful transition efforts.
• FDA authorizations for IQOS, General snus, and ZYN nicotine pouches, including MRTP orders, validate the scientific substantiation and market potential of SFPs.
• The reacquisition of full IQOS commercialization rights in the U.S. positions the company for significant growth in the world's largest smoke-free market.
• The company's cumulative total shareholder return of $247.10 as of December 31, 2025, significantly outperformed its Peer Group ($128.30) and the S&P 500 Index ($196.20) over the past five years.
• An 8.9% increase in the quarterly dividend to $1.47 per common share (annualized $5.88) signals confidence in future cash flows.
• Interest expense, net, decreased by 15.5% to $966 million, primarily due to lower market interest rates and favorable derivative financial instruments.
• The effective tax rate decreased by 5.0 percentage points to 19.7% in 2025, contributing to higher net earnings.
• A new production facility in Lviv, Ukraine, was completed and commenced local production in April 2024, demonstrating resilience and continued investment in key markets.

Negatives

• Cigarette shipment volume continued its decline, falling by 1.5% in 2025, reflecting ongoing challenges in the combustible tobacco segment.
• A goodwill impairment charge of $41 million was recorded in the Europe segment in 2025, indicating a reassessment of asset values.
• A pre-tax charge of $176 million was incurred in 2025 due to the Germany excise tax classification litigation for TEREA consumables, impacting profitability.
• A pre-tax loss of $94 million was recorded in 2025 from the expected sale of consumer accessories and other businesses.
• Higher marketing, administration, and research costs, as well as increased manufacturing costs, partly offset revenue gains.
• Restructuring charges increased to $241 million in 2025 from $180 million in 2024, reflecting ongoing operational adjustments.
• Increased working capital requirements in 2025, particularly for inventories and excise tax payments (including $0.8 billion for the German HTP surcharge), impacted operating cash flows.
• Net cash used in investing activities increased significantly to $4.0 billion in 2025 from $1.1 billion in 2024, partly due to higher capital expenditures and changes in cash collateral for derivatives.
• Total debt increased to $48.8 billion at year-end 2025 from $45.7 billion in 2024.
• An after-tax impairment charge of $146 million was recorded in 2025 for an equity method investment within the Wellness business, driven by a lower likelihood of success for certain projects.
• Multiple litigations related to ZYN nicotine pouches have been filed in the U.S., alleging nicotine addiction, defective design, marketing to minors, and misrepresentation of health risks.

Risks

• Unsuccessful efforts to introduce, commercialize, and grow smoke-free products in existing and new markets could materially adversely impact financial results and future growth prospects.
• Regulators may prohibit or significantly restrict the commercialization of smoke-free products or the communication of scientifically substantiated information and claims.
• Actions of some market participants, such as inappropriate marketing of e-vapor products to youth, may unfavorably impact public opinion and/or mischaracterize the health consequences of SFPs.
• Significant usage of products among youth or non-nicotine users, whether actual or perceived, could lead to reputation damage and more restrictive regulatory approaches.
• Consumption of tax-paid cigarettes continues to decline in many markets due to increased taxes, governmental actions, diminishing social acceptance, health concerns, competition, and illicit products.
• Governmental actions aimed at increasing regulatory requirements could significantly decrease demand for brands or increase operating costs.
• Regulatory initiatives that lead to commoditization of tobacco products or impede adult consumers' ability to access and convert to SFPs could materially adversely affect financial results.
• The success of the business in the United States is dependent on an evolving legal and regulatory framework, and FDA actions or inactions may have a material adverse impact.
• Intense competition, including from lower-price products, innovative products, and illicit trade, could materially adversely affect profitability and results of operations.
• Inability to anticipate changes in adult consumer preferences or adapt product offerings could lead to missed opportunities and reduced competitiveness.
• The financial and business performance of smoke-free products is less predictable than the cigarette business, with varying paces of adoption.
• Inability to introduce new products, enter new markets, maintain sufficient production capacity, or improve margins could limit profit growth.
• Failure to attract, motivate, and retain global talent and effectively align organizational design with transformation goals may impair strategic objectives.
• Significant increases in cigarette-related taxes may disproportionately affect profitability and competitiveness.
• Unsuccessful efforts to differentiate smoke-free products and cigarettes with respect to taxation could materially adversely affect SFP unit margins.
• Changes in the earnings mix and changes in tax laws may result in significant variability in effective tax rates.
• Ability to receive payments from foreign subsidiaries or repatriate royalties and dividends could be restricted by local currency exchange controls and other regulations.
• Disruptions in the credit markets or changes to credit ratings may adversely affect the business and increase borrowing costs.
• Requirement to write down assets due to impairment could have a material adverse effect on results of operations or financial position.
• The continuation and consequences of the war in Ukraine may adversely impact business, results of operations, cash flows, and financial position, including potential material impairment of Russian assets.
• Use of third-parties for distribution, manufacturing, and services may negatively impact product quality, availability, and supply chain control.
• Risks related to the natural environment and related legal or regulatory developments (e.g., extreme weather, carbon taxes) may have a negative impact on business and results of operations.
• Government mandated prices, production control programs, and shifts in crops may increase the cost or reduce the quality of tobacco and other agricultural products.
• A prolonged disruption of facilities, especially the ZYN production facility in Kentucky, could have a material adverse effect on business.
• Product recalls due to quality or safety standards failures could have a material adverse effect on business, reputation, and financial position.
• Economic, regulatory, and political developments, natural disasters, pandemics, or conflicts in numerous countries may adversely impact international operations.
• Inability to adequately protect intellectual property rights, or disputes relating to them, could harm the business.
• Legal, regulatory, and reputational risks associated with the research, development, and commercialization of non-recreational cannabinoid products.
• Revenues may be materially adversely affected by counterfeiting, contraband, cross-border purchases, and other illicit products.
• Significant dependence on information technology networks and systems, making the company vulnerable to cybersecurity incidents or attacks.
• Failure or inability to adhere to privacy, data, artificial intelligence, and information security laws could result in reputational harm and legal liability.
• Increasing use of artificial intelligence-based solutions in business could result in reputational harm, legal liability, and adversely affect operating results.
• Inability to successfully identify, complete, or realize the benefits from strategic acquisitions, divestitures, joint ventures, or investments.

Future Outlook

The company anticipates a broadly stable total PMI cigarette and smoke-free product shipment volume for the full year 2026, with high-single digit smoke-free product shipment volume growth and a cigarette shipment volume decline of around 3%. The estimated total international industry volume for cigarettes and heated tobacco units (excluding China and the U.S.) is expected to decline by approximately 2% in 2026. The effective tax rate for 2026 is estimated to be around 21.5%, excluding discrete tax events. Net cash provided by operating activities is projected to be around $13.5 billion in 2026, with capital expenditures expected to range from $1.4 billion to $1.6 billion, primarily supporting the smoke-free business. The global tariff environment is expected to remain volatile throughout 2026, and the EU Tobacco Excise Directive revision is contemplated for implementation by January 1, 2028.

Management Comments

• Our strategic priority is the continued introduction, commercialization, and growth of our SFPs and if these efforts are not successful, in key markets or systematically, our financial results and future growth prospects may be materially adversely impacted.
• We believe that when better alternatives to cigarettes exist, the discussion should not be whether these alternatives should be made available to the more than one billion people who smoke cigarettes today, but how fast they can be made available, and within what regulatory framework to maximize their adoption by adult smokers while minimizing unintended use.
• We advocate for regulatory frameworks that are based on a continuum of risk where non-combustible products fall below combustible cigarettes.
• We believe that regulation and taxation should differentiate between cigarettes and products that present, are likely to present, or have the potential to present less risk of harm to adult smokers who switch to these products versus continued smoking.
• Importantly, regulation must include measures designed to prevent initiation by youth and non-nicotine users.
• We oppose blanket bans and unreasonable restrictions of products that have the potential to present less risk of harm compared to continued cigarette smoking.
• We support regulation that sets clear standards for all SFP categories and propels innovation to benefit adult smokers who would otherwise continue to smoke cigarettes.
• Management assessed the effectiveness of PMIs internal control over financial reporting as of December 31, 2025... Based on this assessment, management determined that, as of December 31, 2025, PMI maintained effective internal control over financial reporting.

Industry Context

StockSavvy.ai notes that Philip Morris International's 2025 performance reflects a broader industry trend of declining combustible tobacco consumption offset by significant investment and growth in smoke-free alternatives. The company's strategic pivot towards a 'smoke-free future' aligns with evolving public health concerns and regulatory pressures globally. The success of IQOS and ZYN, bolstered by FDA authorizations, positions PMI as a leader in the reduced-risk product category. However, the industry continues to grapple with intense competition, dynamic and often restrictive regulatory environments, and the persistent challenge of illicit trade. Geopolitical instability, particularly the war in Ukraine, and inflationary pressures add layers of complexity to global operations and supply chains, impacting all major players in the consumer goods sector.

Comparison to Industry Standards

• PMI's cumulative total shareholder return of $247.10 from December 31, 2020, to December 31, 2025, significantly outperformed its defined Peer Group (which includes major consumer goods and tobacco companies like Altria, British American Tobacco, Coca-Cola, PepsiCo, and Nestlé) which returned $128.30, and the S&P 500 Index which returned $196.20.
• The company's smoke-free products are available in 106 markets, and modern oral pouches in 56 markets, demonstrating a broad global commercialization footprint for its reduced-risk portfolio, comparable to or exceeding many competitors' reach in these emerging categories.
• Marlboro, PMI's leading international cigarette brand, accounted for approximately 43% of its total 2025 cigarette shipment volume, maintaining its position as the world's best-selling international cigarette, a benchmark for brand strength in the combustible segment.
• ZYN is identified as the leading smoke-free product brand in the U.S. market, indicating a strong competitive position in a key growth category against both traditional tobacco companies and new market entrants.

Management Changes

Corporate Governance

Legal Proceedings

• Seven health care cost recovery cases are pending against the company, its subsidiaries, or indemnitees in Brazil (1), Korea (1), and Nigeria (5), seeking reimbursement for alleged smoking-related health care costs and other damages.
• One public civil action is pending against a subsidiary in Venezuela, seeking stricter regulations on tobacco products and a fund for smoking-related health care costs.
• Multiple putative class actions and individual complaints have been filed in U.S. federal courts (e.g., Kelly, Bates-Ferreira, Palmer, Lendinara, Norris, Friedman, Maultsby, Dykes, Siegert) against PMI and its subsidiaries related to ZYN nicotine pouches, alleging nicotine addiction, defective design, marketing to minors, and misrepresentation of health risks.
• The Mayor and City Council of Baltimore filed a case alleging violations of the city's Consumer Protection Ordinance regarding ZYN marketing.
• An anti-corruption trial is ongoing in Rome, Italy, against the Italian subsidiary (PM Italia) and individuals for alleged contravention of anti-corruption laws and disruption of trade freedom, with British American Tobacco Italia S.p.a. seeking EUR50 million in damages.
• The Brazilian Tax Authority has issued assessments alleging underpayments of indirect taxes for 2020 ($27 million) and 2021 ($41 million), with further assessments expected.
• Multiple patent infringement actions have been filed by Future Technology K.K. (FTKK) against Sojitz Corporation (PMJL's importer and distributor) in Japan concerning TEREA and SENTIA consumables, with some claims withdrawn or rejected by the court/Customs, but others remain pending.

Related Party Transactions

• Net revenues from Megapolis Group (PMI's distributor in Russia, in which PMI holds a 23% equity interest) totaled $2,805 million in 2025.
• Total net revenues from all related parties amounted to $4,582 million in 2025.
• Expenses with other related parties were $210 million in 2025.
• Receivables from Megapolis Group were $568 million and from other related parties were $271 million as of December 31, 2025.
• Payables to other related parties were $37 million as of December 31, 2025.
• PMI holds a 23% equity interest in JSC TK Megapolis, with a carrying value of $303 million as of December 31, 2025, and approximately $523 million of cumulative foreign currency translation losses associated with TKM.
• PMI holds a 49% equity interest in Emirati Investors-TA (FZC) (EITA), which in turn holds a 51% interest in Socit des Tabacs Algro-Emiratie (STAEM), an Algerian joint venture.
• PMI acquired a controlling interest of 54.25% in United Tobacco Company (UTC) in May 2024, an entity in Egypt that manufactures products under license for PMI's Egyptian subsidiary.
• PMI acquired an indirect economic interest of 14.7% in Eastern Company, Egypt's largest cigarette manufacturer, in May 2024, and guarantees certain credit facilities and repayment of bank loan liabilities for Eastern Company up to $385 million until 2034.
• An after-tax impairment charge of $146 million was recorded in 2025 for an equity method investment within the Wellness business.
• The implementation of the RBH (Canada) Plan resulted in $303 million of pre-tax income from dividend income net of the corresponding decrease in the carrying value of the RBH investment in 2025; RBH remains deconsolidated.

Stakeholder Impact

• Shareholders: Benefited from strong diluted EPS growth (60.6%) and an 8.9% increase in quarterly dividends. However, they face risks from ongoing litigation, geopolitical uncertainties, and potential future dilution from capital raises.
• Employees: Affected by internal reorganizations and restructuring activities, such as the cessation of combustible tobacco production in Germany, but the company emphasizes attracting and retaining talent and maintaining global EQUAL-SALARY certification.
• Customers: Benefit from expanded availability of smoke-free products in more markets and product innovation, but may experience impacts from promotional activities and potential market disruptions.
• Suppliers: Engaged through supply chain financing programs, but face potential disruptions from geopolitical events and reliance on third-party manufacturing.
• Creditors: The company's increased total debt ($48.8 billion) and ongoing financing activities are relevant, though strong credit ratings and access to credit facilities mitigate immediate concerns.
• Regulatory Bodies: The company actively engages with regulators on science-based frameworks for smoke-free products, but faces challenges from evolving and often restrictive regulations and ongoing legal disputes.

Next Steps

• Reporting will reflect the new International Smoke-Free, International Combustibles, and U.S. segments as of the first quarter of 2026.
• The company expects an estimated total international industry volume decline of around 2% for cigarettes and heated tobacco units (excluding China and the U.S.) for the full year 2026.
• Total PMI cigarette and smoke-free product shipment volume is expected to be broadly stable for the full year 2026, with high-single digit SFP shipment volume growth and a cigarette shipment volume decline of around 3%.
• The estimated effective tax rate for 2026 is projected to be around 21.5%, excluding discrete tax events.
• Net cash provided by operating activities is expected to be around $13.5 billion in 2026.
• Total capital expenditures in 2026 are expected to be $1.4 billion to $1.6 billion, predominantly for investments supporting the smoke-free business.
• An oral hearing is expected by the third quarter of 2026 for the appeal ruling on the legality of the heated tobacco product surcharge in Germany.
• Japan's multi-year tax plan includes excise tax harmonization for heated tobacco products with cigarettes in two steps: April 1, 2026, and October 1, 2026.
• The first increase in the harmonized HTP and cigarette excise tax in Japan will occur in April 2027.
• The deadline for completion of all fact and expert discovery in the ZYN litigation (Kelly, Palmer, Lendinara, and Friedman cases) is June 26, 2026, with trials set to begin on December 7, 2026.
• A final hearing for the PM Italia anti-corruption trial is scheduled for April 29, 2026, with a decision expected thereafter.
• A new shelf registration statement is planned to be filed in February 2026.
• The new $2.0 billion senior unsecured revolving credit facility became effective on January 29, 2026.
• The existing multi-year 1.5 billion revolving credit facility has been extended to January 29, 2029.
• The Eleventh Session of the Conference of the Parties (CoP11) took place in November 2025, and CoP12 will take place in 2027.
• The EU Commission announced its intention to propose a revision of the legislative framework on tobacco control (including the TPD) in 2026.

Key Dates

Recommendation

PMI demonstrates robust financial performance, driven by strong growth in its smoke-free product portfolio and successful strategic initiatives like the reacquisition of IQOS U.S. rights and FDA authorizations. The company's outperformance against its peer group and the S&P 500 in TSR is notable. However, the persistent decline in combustible tobacco volumes, substantial ongoing litigation related to ZYN, and the unpredictable geopolitical situation in Russia and Ukraine introduce considerable uncertainties and potential liabilities. The company's strategy to transition to a smoke-free future is promising but faces significant regulatory hurdles and competitive pressures. Therefore, a 'Hold' recommendation is appropriate, acknowledging the company's strengths while recognizing the material risks that could impact future performance.

Keywords

Philip Morris International, PMI, 10-K, Annual Report, Smoke-Free Products, IQOS, ZYN, Heated Tobacco, Nicotine Pouches, Cigarettes, Financial Results, Earnings, Revenue, FDA Authorization, Regulatory Environment, Litigation, ESG, Corporate Governance, Capital Expenditures, Debt, Russia-Ukraine Conflict, Wellness, Intellectual Property